Children's Hospital is part of the UPMC family.
This research study is taking a look at a new regimen of medicines used in intestine transplantation to see how they work to prevent rejection. Traditional combinations of tacrolimus, steroids and thymoglobulin can cause suppression of the function of lymphocytes, delayed growth and development of bones. Chronic rejection, an additional effect of this combination, may occur, causing further complications. In this study, through the use of alemtuzumab in place of thymoglobulin, researchers hope to understand its long-term effects on blood cells and its ability to lower the rate of rejection with possible elimination of the use of steroids.
Eligible candidates will include males and females, under 25 years of age, who are about to receive an intestinal transplant and have not been diagnosed with cancer or an infectious disease such as hepatitis.
Boys: 25 years and younger
Girls: 25 years and younger
Participants will undergo various routine procedures for transplant patients, while receiving alemtuzumab throughout the study duration.
Visits: Multiple, as with conventional post-transplant care
Duration: 1 year
Pediatric Transplantation Department, Children’s Hospital of Pittsburgh of UPMC
Rakesh Sindhi, MD
For more information, please contact:
Katie Hindes Kalata, BS, MPH
Kym Smith, BS
Children's Hospital's main campus is located in the Lawrenceville neighborhood. Our main hospital address is:
Children’s Hospital of Pittsburgh of UPMC
One Children’s Hospital Way
4401 Penn Ave.
Pittsburgh, PA 15224
In addition to the main hospital, Children's has many convenient locations in other neighborhoods throughout the greater Pittsburgh region.
With myCHP, you can request appointments, review test results, and more.
For questions about a hospital bill call:
To pay your bill online, please visit UPMC's online bill payment system.
Interested in giving to Children's Hospital? Visit Children's Hospital of Pittsburgh Foundation's website to: